DHR – Danaher Corporation
Danaher CorporationDHR
$189.60Name : Danaher Corporation
Sector : Healthcare
Industry: Diagnostics & Research
Mark. Cap: $134,179,807,232.00
EPSttm : 5.02
Danaher Corporation
$189.60
3.11%$5.71
DHR — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
0.86
Margin Of Safety %
14
Put/Call OI Ratio
0.72
EPS Next Q Diff
0.19
EPS Last/This Y
3.34
EPS This/Next Y
0.7
Price
189.57
Target Price
263.48
Analyst Recom
1.44
Performance Q
-17.79
Upside
-41.4%
Beta
0.97
Ticker: DHR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-02 | DHR | 206.02 | 1.39 | 0.46 | 73905 |
| 2026-03-04 | DHR | 204.73 | 1.32 | 2.09 | 75587 |
| 2026-03-05 | DHR | 201.62 | 1.08 | 2.13 | 74920 |
| 2026-03-09 | DHR | 198.77 | 1.09 | 0.71 | 64355 |
| 2026-03-10 | DHR | 195.24 | 1.04 | 1.43 | 65447 |
| 2026-03-11 | DHR | 195.07 | 1.03 | 3.11 | 66091 |
| 2026-03-12 | DHR | 186.25 | 1.02 | 2.58 | 66917 |
| 2026-03-17 | DHR | 195.23 | 0.94 | 0.84 | 67133 |
| 2026-03-18 | DHR | 191.44 | 0.90 | 0.60 | 68764 |
| 2026-03-19 | DHR | 190.1 | 0.88 | 0.75 | 69961 |
| 2026-03-20 | DHR | 189.32 | 0.83 | 0.88 | 73989 |
| 2026-03-23 | DHR | 190.03 | 0.86 | 1.31 | 54089 |
| 2026-03-24 | DHR | 190.08 | 0.86 | 0.65 | 55606 |
| 2026-03-25 | DHR | 187.17 | 0.78 | 3.57 | 62831 |
| 2026-03-26 | DHR | 188.04 | 0.80 | 0.30 | 63526 |
| 2026-03-27 | DHR | 181.53 | 0.74 | 1.60 | 68231 |
| 2026-03-30 | DHR | 183.94 | 0.72 | 0.84 | 65272 |
| 2026-03-31 | DHR | 189.58 | 0.72 | 0.24 | 65969 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-02 | DHR | 206.01 | 3.1 | 1999.3 | 8.41 |
| 2026-03-03 | DHR | 204.07 | 3.1 | 2075.5 | 8.41 |
| 2026-03-04 | DHR | 204.76 | 3.1 | 2153.6 | 8.41 |
| 2026-03-05 | DHR | 201.92 | 3.1 | 2049.2 | 8.41 |
| 2026-03-06 | DHR | 195.54 | 3.1 | 1941.9 | 8.41 |
| 2026-03-09 | DHR | 198.84 | 3.1 | 2233.7 | 8.41 |
| 2026-03-10 | DHR | 195.23 | 3.1 | 2024.0 | 8.41 |
| 2026-03-11 | DHR | 195.07 | 3.1 | 2127.2 | 8.41 |
| 2026-03-12 | DHR | 186.22 | 3.1 | 1860.8 | 8.41 |
| 2026-03-13 | DHR | 187.46 | 3.1 | 2169.9 | 8.41 |
| 2026-03-17 | DHR | 195.23 | 3.1 | 2251.3 | 8.41 |
| 2026-03-18 | DHR | 191.45 | 3.1 | 2016.5 | 8.41 |
| 2026-03-19 | DHR | 190.13 | 3.1 | 1248.9 | 8.41 |
| 2026-03-20 | DHR | 189.32 | 3.1 | 760.3 | 8.41 |
| 2026-03-23 | DHR | 190.07 | 3.1 | 798.0 | 8.41 |
| 2026-03-24 | DHR | 190.10 | 3.1 | 782.5 | 8.41 |
| 2026-03-25 | DHR | 187.15 | 3.1 | 706.3 | 8.41 |
| 2026-03-26 | DHR | 188.04 | 3.1 | 802.5 | 8.41 |
| 2026-03-27 | DHR | 181.52 | 3.1 | 625.2 | 8.41 |
| 2026-03-30 | DHR | 183.85 | 3.1 | 850.8 | 8.41 |
| 2026-03-31 | DHR | 189.57 | 3.1 | 936.5 | 8.41 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-02 | DHR | -1.76 | 1.94 | 1.10 |
| 2026-03-03 | DHR | -1.76 | 1.94 | 1.10 |
| 2026-03-04 | DHR | -1.76 | 1.94 | 1.10 |
| 2026-03-05 | DHR | -1.76 | 1.94 | 1.10 |
| 2026-03-06 | DHR | -1.76 | 1.94 | 1.10 |
| 2026-03-09 | DHR | -1.76 | 1.86 | 1.10 |
| 2026-03-10 | DHR | -1.76 | 1.86 | 1.10 |
| 2026-03-11 | DHR | -1.76 | 1.86 | 0.98 |
| 2026-03-12 | DHR | -1.76 | 1.86 | 0.98 |
| 2026-03-13 | DHR | -1.76 | 1.86 | 0.98 |
| 2026-03-17 | DHR | -1.76 | 1.89 | 0.98 |
| 2026-03-18 | DHR | -1.76 | 1.89 | 0.98 |
| 2026-03-19 | DHR | -1.76 | 1.89 | 0.98 |
| 2026-03-20 | DHR | -1.76 | 1.89 | 0.98 |
| 2026-03-23 | DHR | -1.76 | 1.88 | 0.98 |
| 2026-03-24 | DHR | -1.76 | 1.88 | 0.98 |
| 2026-03-25 | DHR | -1.76 | 1.88 | 0.86 |
| 2026-03-26 | DHR | -1.76 | 1.88 | 0.86 |
| 2026-03-27 | DHR | -1.76 | 1.88 | 0.86 |
| 2026-03-30 | DHR | -1.76 | 1.88 | 0.86 |
| 2026-03-31 | DHR | -1.76 | 1.88 | 0.86 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.68
Avg. EPS Est. Current Quarter
1.94
Avg. EPS Est. Next Quarter
1.87
Insider Transactions
-1.76
Institutional Transactions
1.88
Beta
0.97
Average Sales Estimate Current Quarter
6001
Average Sales Estimate Next Quarter
6148
Fair Value
215.75
Quality Score
85
Growth Score
71
Sentiment Score
55
Actual DrawDown %
36
Max Drawdown 5-Year %
-39.8
Target Price
263.48
P/E
37.54
Forward P/E
20.82
PEG
2.4
P/S
5.46
P/B
2.55
P/Free Cash Flow
25.49
EPS
5.05
Average EPS Est. Cur. Y
8.41
EPS Next Y. (Est.)
9.11
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
14.71
Relative Volume
1.14
Return on Equity vs Sector %
-20.6
Return on Equity vs Industry %
-4.2
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
936.5
◆
DHR
Healthcare
$189.60
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
41.9
Range 1M
31.4%
Sup Dist
4.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
7.8%
EPS NY
8.3%
52W%
25.8%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+14.8% upside
Upside
+14.8%
Quality
85
MoS
14%
Danaher CorporationSector: Healthcare
Industry: Diagnostics & Research
Employees: 58000
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
DHR
Latest News
—
Caricamento notizie per DHR…
stock quote shares DHR – Danaher Corporation Stock Price stock today
news today DHR – Danaher Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch DHR – Danaher Corporation yahoo finance google finance
stock history DHR – Danaher Corporation invest stock market
stock prices DHR premarket after hours
ticker DHR fair value insiders trading